Anixa Biosciences, Inc. (ANIX) analyst actions
Rating and price-target actions on ANIX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ANIX overview →
3 measured ANIX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial | Press release | +2.42% | +2.05% | |
| Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial | Press release | +1.00% | -0.65% | |
| Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial | Press release | +0.00% | -1.11% |
Keep exploring
More ANIX: earnings → · SEC filings → · ANIX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
| Entera Bio Ltd. - Ordinary Shares (ENTX) | 217 | 0.00% | 46% |
| Precipio, Inc. (PRPO) | 217 | +0.51% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.